Eight specialist agents, one MDT recommendation

OncoSphere AI uses a parallel multi-agent architecture: eight virtual specialty agents independently analyze a patient case against specialty guidelines and literature, then assemble a single guideline-anchored MDT recommendation. Advisory clinical decision support.

Request a Pilot

OncoSphere AI is built on a parallel reasoning framework. Rather than a single generic model, it runs a coordinated ensemble of eight domain-specialized agents. Each agent independently analyzes the patient’s structured and unstructured data against its own specialty-specific guidelines and contemporary peer-reviewed literature. Their outputs are then synthesized into one integrated, guideline-anchored recommendation for the physician to review.

The workflow

The eight agents

Medical Oncology

Systemic therapy options, NCCN-anchored regimen selection, and rationale tied to the patient’s stage, biomarkers, and prior lines.

Radiation Oncology

Indications, target/technique considerations, and follow-up, aligned to guideline criteria.

Surgical Oncology

Resectability assessment and procedure considerations against NCCN/AJCC criteria.

Pathology

Histology, IHC, and molecular findings — reported exactly as documented, including negatives that rule out targeted therapy.

Radiology

Imaging interpretation, measurements, and AJCC/RECIST-aligned staging.

Pharmacy

Dosing, preparation/administration, interactions, and supportive-care guidance.

Clinical Research

Trial concepts and eligibility considerations matched to the case.

Nurse Navigation

Care-coordination checklist and intake worksheet to keep the plan moving.

Adaptive by design

System telemetry from the ASCO 2026 validation showed adaptive compute behavior: the platform autonomously allocated 1.73× more reasoning to complex, refractory cases than to standard scenarios — spending effort where the case warrants it.